Posted on December 21, 2015 by Sitemaster
The question of whether PSA kinetics (e.g., PSA doubling time and PSA velocity) can be used to accurately project risk for prostate cancer progression and mortality is still not definitively known (although it is much debated). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: kinetics, localized, prognosis, PSA | 14 Comments »
Posted on October 27, 2011 by Sitemaster
Researchers at Johns Hopkins have provided data to support the hypothesis that, in men being treated with novel, non-hormonal agents for non-metastatic, non-castrate, biochemically recurrent prostate cancer after first-line therapy, changes in PSA kinetics may be indicative of metastasis-free survival. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: endpoint, kinetics, metastasis-free, PSA, survival | Leave a comment »
Posted on May 4, 2010 by Sitemaster
The role of PSA kinetics (i.e., PSA doubling time and PSA velocity) in the early diagnosis of prostate cancer and in the monitoring of patients on active surveillance protocols has been controversial. We now have some more definitive data. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, doubling time, kinetics, PSA, PSADT, PSAV, velocity | 6 Comments »
Posted on April 15, 2009 by Sitemaster
There are several articles that may be of interest to readers in the April issue of the AUA News, which is now available on line. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, Diagnosis, kinetics, prognosis, PSA, risk, saturation | 1 Comment »